MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common...
$116,870K
Proceeds from issuance of
common stock-At The...
$9,341K
Other
$274K
Proceeds from exercises
of stock options
$107K
Net cash provided by
financing activities
$126,399K
Canceled cashflow
$193K
Net change in cash,
cash equivalents and...
$19,104K
Canceled cashflow
$107,295K
Payments for repurchase
of common stock for...
$193K
Stock-based compensation
expense
$19,099K
Impairment loss on
right-of-use asset
$10,733K
Reduction in carrying
amount of right-of-use...
$6,434K
Depreciation and
amortization
$1,959K
Prepaid expenses and
other current and...
-$1,144K
Accounts receivable
-$701K
Other
$99K
Proceeds from maturities
of marketable...
$219,080K
Net cash used in
operating activities
-$98,694K
Net cash used in
investing activities
-$8,601K
Canceled cashflow
$40,169K
Canceled cashflow
$219,080K
Net loss
-$104,994K
Purchase of marketable
securities
$227,074K
Deferred revenue
-$18,836K
Accrued expenses and
other current...
-$6,049K
Operating lease liability
-$5,774K
Accretion of premium on
marketable securities
$2,742K
Accounts payable
-$468K
Purchases of property and
equipment
$607K
Back
Back
Cash Flow
source: myfinsight.com
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)